Merck’s Q3 2024 Report: Mixed Results with Keytruda Shining and Gardasil Struggling
Merck, a leading pharmaceutical company, shared its financial results for the third quarter of 2024, surprising some investors with better-than-expected earnings and revenue. The star of the show was Keytruda, their top-selling cancer drug, which continued to bring in strong sales. Newly launched tr